Esophageal Cancer
1L unresectable advanced/recurrent/metastatic ESCC1
Esophageal Cancer
1L unresectable advanced/recurrent/metastatic ESCC1
Fixed nivolumab dosing (Q3W)
Weight-based nivolumab dosing (Q2W)
1L, first-line; ESCC, esophageal squamous cell carcinoma; IV, intravenous; PD, progressive disease; QxW, every x weeks.
1. Opdivo® (nivolumab). Hong Kong Prescribing Information; Hong Kong: Bristol-Myers Squibb; 2023.